Early-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM) (EMBLEM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Sherri Katz
- Phone Number: (613) 737-7600
- Email: skatz@cheo.on.ca
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L1
- Recruiting
- The Children's Hospital of Eastern Ontario
-
Contact:
- Sherri Katz, Clinical Study Lead
- Phone Number: 2956 (613) 737-7600
- Email: skatz@cheo.on.ca
-
Toronto, Ontario, Canada, M5G 1X5
- Recruiting
- Mount Sinai Hospital
-
Contact:
- Adel Mohamed, Site Lead
- Phone Number: 7396 416-586-4800
- Email: adel.mohamed@sinaihealth.ca
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3J1
- Recruiting
- Montreal Children's Hospital
-
Contact:
- Gabriel Altit, Co-Site Lead
- Email: gabriel.altit@mcgill.ca
-
Contact:
- Larry Lands, Co-Site Lead
- Email: larry.lands@mcgill.ca
-
Montréal, Quebec, Canada, H3T 1C5
- Active, not recruiting
- CHU-Sainte Justine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Infants born at <29 weeks gestation;
- currently <36 weeks PMA.
Exclusion Criteria:
- Known interstitial lung disease, congenital lung anomaly, ciliary dysfunction, immunodeficiency, cystic fibrosis, neuromuscular disease, or structural heart disease (other than atrial septal defect/hemodynamically insignificant ventricular septal defect/patent ductus arteriosus);
- genetic syndrome or congenital anomaly;
- contraindications for MRI or transport;
- invasive or non-invasive ventilation that cannot be safely removed for MRI;
- current respiratory infection;
- family cannot speak English/French;
- transferred to another hospital prior to baseline study visit
- not receiving follow-up at one of the study centres.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Severe Post-prematurity Respiratory Disease (PRD)
Time Frame: The evaluation will be conducted at regular intervals of every 3 months, commencing at 36 weeks PMA and continuing until the child reaches 18 months corrected age
|
PRD will be defined based on the consensus definition of the Prematurity and Respiratory Outcomes Program.
This composite outcome characterizes clinically relevant persistent respiratory morbidity in early life.
It will be evaluated every 3 months from 36 weeks PMA to 18 months corrected age through parent questionnaire and chart review.
Severe PRD is defined as a positive response to any of the following: ≥2 respiratory-related hospitalizations, home oxygen at 3 months corrected age or any home respiratory support, systemic corticosteroid or pulmonary vasodilators after discharge home, chronic respiratory symptoms (cough without cold or wheeze at least once per week) despite concurrent inhaled corticosteroids in ≥ 2 questionnaires, or death secondary to a cardiopulmonary cause.
PRD has been used as a clinical outcome in cohort studies and an American Thoracic Society guideline on optimal neonatal care pathways and predictive perinatal characteristics.
|
The evaluation will be conducted at regular intervals of every 3 months, commencing at 36 weeks PMA and continuing until the child reaches 18 months corrected age
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurodevelopmental Impairment (NDI)
Time Frame: Neurodevelopmental impairment will be determined at the 18-21 months corrected age visit
|
Per the Canadian Neonatal Follow-Up Network protocol, NDI will be determined at the 18-21 months corrected age visit.
Children will be administered the Bayley Scales of Infant and Toddler Development, 4th edition (Bayley-4), assessing infant developmental functioning across five domains.
Cognition, language, and motor subtests are directly assessed by a blinded, trained assessor regarding neonatal history.
The social-emotional and adaptive behavior components are assessed via parental questionnaires.
The Bayley-4 yields standard mean scores of 100±15.
A pediatrician performs a neurological examination to identify signs of cerebral palsy and determine functional level using the Gross Motor Functional Classification System (GMFCS).
Visual and hearing function data are retrieved from the chart.
NDI will be defined as the presence of any of the following: Bayley-4 score <85, cerebral palsy with GMFCS ≥ 2, the requirement for hearing aids/cochlear implants, and bilateral blindness.
|
Neurodevelopmental impairment will be determined at the 18-21 months corrected age visit
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sherri Katz, Children's Hospital of Eastern Ontario
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 486713
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.